Diltiazem and Metoprolol Have Similar Overall Side Effect Profiles, Though the Types of Side Effects Differ
Both diltiazem (Cardizem) and metoprolol cause side effects at comparable rates overall, but the specific adverse effects differ between the two medications. The most recent meta-analysis found metoprolol associated with 26% lower risk of adverse events (10% vs 19% with diltiazem), though this difference was modest and the prediction interval crossed unity 1. When examining individual side effects, no significant differences emerged for hypotension or bradycardia specifically 1.
Side Effect Profiles by Drug Class
Metoprolol (Beta-Blocker) Side Effects
The most common adverse effects include 2:
- Lethargy and fatigue (most frequently reported)
- Headache
- Peripheral edema
- Upper respiratory tract symptoms
- Gastrointestinal upset
- Dizziness
- Depression (noted across multiple guidelines) 3
- Reduced libido and impotence 3
- Bronchospasm (rare with beta-1 selective agents like metoprolol, but contraindicated in severe asthma) 2, 4
Diltiazem (Calcium Channel Blocker) Side Effects
The most common adverse effects include 2:
- Dizziness and malaise
- Lethargy
- Headache
- Hot flushes
- Gastrointestinal upset (including rare but serious ileus) 4
- Peripheral edema (common to all calcium channel blockers) 5
- Hypotension (particularly with IV administration) 6
Critical Safety Considerations
Contraindications and Precautions
Metoprolol should be avoided in:
- Severe asthma or poorly controlled reactive airway disease 2, 7
- Severe peripheral arterial disease 4
- Decompensated heart failure with reduced ejection fraction (HFrEF) 2, 7
- AV block greater than first degree without pacemaker 7
Diltiazem should be avoided in:
- Heart failure with LVEF <40% (can worsen HF due to negative inotropic effects) 2, 8
- Decompensated systolic heart failure 7
- AV block greater than first degree without pacemaker 7
- Accessory conduction pathways (WPW with AF) 4, 7
Drug Interaction Risks
A critical safety concern: Profound bradycardia can result from combining beta-blockers with diltiazem 4. This combination must be used with extreme caution.
Diltiazem is both a substrate and inhibitor of CYP3A4, creating significant drug interaction potential 7, 9. Most notably, diltiazem increases bleeding risk when combined with apixaban or rivaroxaban compared to metoprolol, with a rate difference of 5.4 per 1000 person-years and higher risk with doses >120 mg/day 10.
Clinical Efficacy Context
While side effect profiles are similar overall, diltiazem demonstrates superior efficacy for rate control in atrial fibrillation 11, 12. In the most recent meta-analyses, diltiazem achieved:
- Higher rate control success (OR 1.92) 12
- Shorter onset time 11
- Lower ventricular rates 11
- Reduced NT-proBNP levels and improved symptoms in permanent AF 13
Quality of Life Considerations
Subjective well-being tends to improve with diltiazem but deteriorate with metoprolol 14. In dose-response studies, contentment and vitality improved with increasing diltiazem doses but showed dose-related deterioration with metoprolol 14. Depression is specifically associated with beta-blocker therapy, while calcium channel blockers like diltiazem cause less psychological depression 3.
Practical Clinical Algorithm
Choose metoprolol when:
- Patient has heart failure with reduced ejection fraction
- Concurrent coronary artery disease with prior MI
- Patient cannot tolerate peripheral edema
- Taking factor Xa inhibitors (apixaban/rivaroxaban)
Choose diltiazem when:
- Preserved left ventricular function
- Reactive airway disease or asthma
- Depression or fatigue concerns
- Rate control for atrial fibrillation is primary goal
- Peripheral arterial disease present
Avoid both or use extreme caution when:
- Significant AV block without pacemaker
- Severe hypotension
- Combining the two medications together